CA3112073A1 - Aromatic compounds and pharmaceutical uses thereof - Google Patents
Aromatic compounds and pharmaceutical uses thereof Download PDFInfo
- Publication number
- CA3112073A1 CA3112073A1 CA3112073A CA3112073A CA3112073A1 CA 3112073 A1 CA3112073 A1 CA 3112073A1 CA 3112073 A CA3112073 A CA 3112073A CA 3112073 A CA3112073 A CA 3112073A CA 3112073 A1 CA3112073 A1 CA 3112073A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- atoms
- double bonds
- alkyl group
- heteroatoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
- C07C65/28—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/64—Monocyclic acids with unsaturation outside the aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/16—Acetic acid esters of dihydroxylic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862744461P | 2018-10-11 | 2018-10-11 | |
| US62/744,461 | 2018-10-11 | ||
| PCT/IB2019/001139 WO2020074964A1 (en) | 2018-10-11 | 2019-10-10 | Romatic compounds and pharmaceutical uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3112073A1 true CA3112073A1 (en) | 2020-04-16 |
Family
ID=68655570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3112073A Pending CA3112073A1 (en) | 2018-10-11 | 2019-10-10 | Aromatic compounds and pharmaceutical uses thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12473249B2 (enExample) |
| EP (1) | EP3864001A1 (enExample) |
| JP (2) | JP2022504707A (enExample) |
| KR (1) | KR20210091150A (enExample) |
| CN (2) | CN113166024B (enExample) |
| AU (2) | AU2019358595B2 (enExample) |
| CA (1) | CA3112073A1 (enExample) |
| CL (1) | CL2021000846A1 (enExample) |
| CO (1) | CO2021006087A2 (enExample) |
| EA (1) | EA202190890A1 (enExample) |
| IL (1) | IL282134A (enExample) |
| MA (1) | MA53188A1 (enExample) |
| MX (1) | MX2021003750A (enExample) |
| PH (1) | PH12021550744A1 (enExample) |
| SG (1) | SG11202103011YA (enExample) |
| WO (1) | WO2020074964A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023065200A1 (en) * | 2021-10-21 | 2023-04-27 | Givaudan Sa | Organic compounds |
| WO2024206117A1 (en) | 2023-03-24 | 2024-10-03 | Northsea Therapeutics B.V. | Benzoic acid derivatives for use in methods of treating intestinal failure-associated liver disease in children |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210266A (en) * | 1987-12-03 | 1993-05-11 | Dainippon Pharmaceutical Co., Ltd. | N-substituted mercaptopropanamide derivatives |
| EP0637957B1 (de) | 1992-04-28 | 1997-07-23 | Fresenius AG | Verwendung einer omega-3-fettsäuren enthaltenden emulsion zur herstellung eines parenteral zu verabreichenden arzneimittels zur behandlung von entzündlichen erkrankungen |
| DK1900364T3 (da) | 2001-04-18 | 2014-01-13 | Prometic Biosciences Inc | Fedtsyrer, glycerider og analoger med medium kædelængde som neutrofile overlevelses- og aktiveringsfaktorer |
| RU2341513C2 (ru) * | 2001-06-12 | 2008-12-20 | Веллстат Терапьютикс Корпорейшн | Соединения для лечения метаболических заболеваний |
| US7553867B2 (en) | 2002-09-06 | 2009-06-30 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
| WO2006066894A1 (en) | 2004-12-24 | 2006-06-29 | Ctg Pharma S.R.L. | Compounds for treating metabolic syndrome |
| AU2004210082B2 (en) * | 2003-02-06 | 2011-03-17 | Dompe' Farmaceutici S.P.A. | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them |
| BRPI0407276A (pt) | 2003-02-07 | 2006-01-31 | Prometic Biosciences Inc | ácidos graxos, glicerìdeos e análogos com comprimento de cadeia médio, como estimulantes de eritropoiese |
| ES2530235T3 (es) * | 2003-02-13 | 2015-02-27 | Wellstat Therapeutics Corporation | Compuestos para el tratamiento de trastornos metabólicos |
| PL1648851T3 (pl) | 2003-07-25 | 2007-09-28 | Prometic Biosciences Inc | Wytwarzanie soli średniołańcuchowych kwasów tłuszczowych z metalami |
| ES2372694T3 (es) * | 2003-10-15 | 2012-01-25 | OSI Pharmaceuticals, LLC | Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina. |
| US20070111989A1 (en) | 2003-12-05 | 2007-05-17 | Olivier Bezencon | Novel diazabicyclononene derivatives and use |
| AP2007003939A0 (en) | 2004-09-03 | 2007-04-30 | Prometic Biosciences Inc | Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides |
| US8071580B2 (en) | 2004-10-01 | 2011-12-06 | Prometic Biosciences Inc. | Medium-chain length fatty alcohols as stimulators of hematopoiesis |
| EA200700741A1 (ru) | 2004-10-01 | 2007-08-31 | Прометик Байосайенсиз Инк. | Жирные спирты со средней длиной цепи как стимуляторы гематопоэза |
| TW200724138A (en) * | 2005-03-29 | 2007-07-01 | Sk Corp | Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use |
| CN101218199A (zh) | 2005-05-09 | 2008-07-09 | 阿斯利康(瑞典)有限公司 | 新化合物ⅰ |
| GB0522433D0 (en) | 2005-11-03 | 2005-12-14 | Astrazeneca Ab | Therapeutic agents |
| RU2008136898A (ru) | 2006-02-15 | 2010-03-20 | Санофи-Авентис (Fr) | Азациклил-замещенные арилдигидроизохинолиноны, способ их получения и их применение в качестве лекарственных средств |
| WO2008016007A1 (fr) | 2006-07-31 | 2008-02-07 | Meiji Seika Kaisha, Ltd. | INHIBITEUR DE LA MÉTALLO-β-LACTAMASE |
| JP5526018B2 (ja) * | 2007-03-21 | 2014-06-18 | エミスフェアー・テクノロジーズ・インク | アリルオキシおよびアルキルオキシ安息香酸送達薬剤 |
| WO2008151211A1 (en) * | 2007-06-05 | 2008-12-11 | Sanofi-Aventis | Substituted benzoylamino-indan-2-carboxylic acids and related compounds |
| US9532962B2 (en) | 2007-11-02 | 2017-01-03 | Prometic Pharma Smt Limited | Medium-chain length fatty acids and glycerides as nephroprotection agents |
| JP5473937B2 (ja) | 2007-12-19 | 2014-04-16 | プロメティック・バイオサイエンシーズ・インコーポレイテッド | 膵臓癌の治療のためのゲムシタビンと併用した中鎖脂肪酸、その塩およびトリグリセリド |
| KR20100135793A (ko) * | 2008-03-13 | 2010-12-27 | 바스프 에스이 | 이량체 벤질리덴 말로네이트 |
| CN102088965B (zh) | 2008-05-13 | 2013-05-08 | 根梅迪卡治疗公司 | 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用 |
| JP2012503595A (ja) * | 2008-07-28 | 2012-02-09 | シダンスク ユニバーシティ | 代謝病の治療用の化合物 |
| EP2427416B1 (en) | 2009-05-04 | 2016-03-09 | Prometic Pharma Smt Limited | Substituted aromatic compounds and pharmaceutical uses thereof |
| KR101783817B1 (ko) * | 2009-05-08 | 2017-10-23 | 프로노바 바이오파마 너지 에이에스 | 심혈관 질병, 대사 질병, 및 염증성 질환 분야관련 질병의 치료를 위한 다중 불포화 지방산 |
| EA022120B1 (ru) * | 2009-10-20 | 2015-11-30 | Целльзом Лимитид | Аналоги гетероциклил пиразолопиримидина в качестве ингибиторов jak |
| ES2441665T3 (es) | 2009-11-26 | 2014-02-05 | Genfit | Utilización de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos |
| TWI572352B (zh) | 2012-03-01 | 2017-03-01 | 波麥堤克藥學Smt有限公司 | 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法 |
| US9562041B2 (en) * | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| TWI689490B (zh) | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療纖維化之經取代之芳族化合物及相關方法 |
| TWI742541B (zh) | 2013-03-15 | 2021-10-11 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| WO2015179697A1 (en) | 2014-05-21 | 2015-11-26 | Taxis Pharmaceuticals, Inc. | Compounds for the treatment of bacterial infections |
| SG11201702812PA (en) | 2014-10-10 | 2017-05-30 | Prometic Pharma Smt Ltd | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes |
| GB2543478A (en) | 2015-09-07 | 2017-04-26 | Manchester Metropolitan Univ | Glycomimetics |
| KR102793841B1 (ko) | 2018-05-08 | 2025-04-11 | 가부시키가이샤 아데카 | 화합물, 잠재성 첨가제, 조성물, 경화물, 경화물의 제조 방법 및 조성물의 제조 방법 |
-
2019
- 2019-10-10 MA MA53188A patent/MA53188A1/fr unknown
- 2019-10-10 US US17/284,022 patent/US12473249B2/en active Active
- 2019-10-10 JP JP2021519840A patent/JP2022504707A/ja active Pending
- 2019-10-10 CA CA3112073A patent/CA3112073A1/en active Pending
- 2019-10-10 MX MX2021003750A patent/MX2021003750A/es unknown
- 2019-10-10 CN CN201980067283.2A patent/CN113166024B/zh active Active
- 2019-10-10 SG SG11202103011YA patent/SG11202103011YA/en unknown
- 2019-10-10 EP EP19809143.1A patent/EP3864001A1/en active Pending
- 2019-10-10 AU AU2019358595A patent/AU2019358595B2/en active Active
- 2019-10-10 WO PCT/IB2019/001139 patent/WO2020074964A1/en not_active Ceased
- 2019-10-10 KR KR1020217014095A patent/KR20210091150A/ko active Pending
- 2019-10-10 EA EA202190890A patent/EA202190890A1/ru unknown
- 2019-10-10 CN CN202510894488.5A patent/CN120923343A/zh active Pending
-
2021
- 2021-04-05 PH PH12021550744A patent/PH12021550744A1/en unknown
- 2021-04-05 CL CL2021000846A patent/CL2021000846A1/es unknown
- 2021-04-07 IL IL282134A patent/IL282134A/en unknown
- 2021-05-11 CO CONC2021/0006087A patent/CO2021006087A2/es unknown
-
2024
- 2024-04-30 JP JP2024073580A patent/JP2024122966A/ja active Pending
-
2025
- 2025-07-16 AU AU2025205518A patent/AU2025205518A1/en active Pending
- 2025-10-24 US US19/368,054 patent/US20260184664A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210091150A (ko) | 2021-07-21 |
| CN120923343A (zh) | 2025-11-11 |
| AU2019358595A1 (en) | 2021-05-27 |
| CN113166024A (zh) | 2021-07-23 |
| SG11202103011YA (en) | 2021-04-29 |
| JP2022504707A (ja) | 2022-01-13 |
| EP3864001A1 (en) | 2021-08-18 |
| CN113166024B (zh) | 2025-07-18 |
| JP2024122966A (ja) | 2024-09-10 |
| CL2021000846A1 (es) | 2021-11-12 |
| US20260184664A1 (en) | 2026-07-02 |
| MA53188A1 (fr) | 2021-12-31 |
| US12473249B2 (en) | 2025-11-18 |
| US20210380521A1 (en) | 2021-12-09 |
| IL282134A (en) | 2021-05-31 |
| WO2020074964A1 (en) | 2020-04-16 |
| PH12021550744A1 (en) | 2022-02-21 |
| BR112021006907A2 (pt) | 2021-09-08 |
| AU2019358595B2 (en) | 2025-04-17 |
| EA202190890A1 (ru) | 2021-09-10 |
| AU2025205518A1 (en) | 2025-08-07 |
| MX2021003750A (es) | 2021-06-15 |
| CO2021006087A2 (es) | 2021-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021183628A (ja) | カルビドパおよびl−ドーパプロドラッグならびにそれらの使用方法 | |
| CA3005760C (en) | Compounds and methods for inhibiting production of trimethylamine | |
| PT1751087E (pt) | Derivados de levodopa e as suas composições e utilizações | |
| CN114746430B (zh) | 治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物 | |
| JP4425921B2 (ja) | シクロオキシゲナーゼ−2インヒビターとして作用するジアリール2−(5h)−フラノンの酸化窒素放出プロドラッグ | |
| CN105189438A (zh) | 用于治疗纤维化的经取代的芳族化合物及相关方法 | |
| AU2014202949A1 (en) | Pro-drugs of NSAIAS with very high skin and membranes penetration rates and their new medicinal uses | |
| US20150031651A1 (en) | Prodrugs of vitamine k | |
| WO2021032218A1 (zh) | 一种并环THRβ受体激动剂化合物及其制备方法和用途 | |
| JP2024122966A (ja) | 芳香族化合物およびその医薬用途 | |
| CN110099681A (zh) | 用于治疗口腔干燥症的组合物和方法 | |
| EP2802320A1 (en) | Tricyclic compounds, compositions comprising them and uses thereof | |
| JP2020128379A (ja) | クレアチンプロドラッグ、その組成物、及びその使用方法 | |
| JP2021523934A (ja) | ミトコンドリア脱共役剤として有用なアミノピラジンおよび関連化合物 | |
| US20160214948A1 (en) | Prodrugs of monomethyl fumarate (mmf) | |
| KR101061764B1 (ko) | 신경보호효과를 가지는 피루베이트 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 | |
| JP2015519334A (ja) | 抗血小板薬のプロドラッグ | |
| RU2751770C2 (ru) | Композиции и способы лечения синдрома раздраженного кишечника | |
| TWI811116B (zh) | 含硒元素的查爾酮化合物及其製備方法、包含其的醫藥組合物、以及用於製備預防或治療大腸癌之醫藥組合物的用途 | |
| KR101360579B1 (ko) | 신규 페닐초산 유도체 | |
| BR112021006907B1 (pt) | Compostos aromáticos, composição farmacêutica e usos da referida composição | |
| CN111163765A (zh) | 用于抑制胆碱向三甲胺(tma)的转化的方法 | |
| JPS60146855A (ja) | アニリン誘導体 | |
| BR122025017301A2 (pt) | Compostos aromáticos, composição e usos farmacêuticos destes | |
| CN112574172A (zh) | 一种没食子酸硫化氢衍生物及其制备方法及医药用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220920 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240925 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241004 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241004 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241004 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250124 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250217 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250630 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250630 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250930 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250930 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260324 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260325 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE Effective date: 20260709 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20260715 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260715 |